Search clinical trials for: FF/levocabastine

Total 120 results

GlaxoSmithKline

Completed

A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)

Rhinitis, Allergic, Perennial and Seasonal

Austria
GlaxoSmithKline
Hammersmith Medicines Research

Completed

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

Asthma

Netherlands
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United States
GlaxoSmithKline

Completed

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma (ILA115938)

Asthma

Argentina, Russian Federation, United States, Chile, Thailand
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

AML, Adult

United States
Guy's and St Thomas' NHS Foundation Trust

Unknown

Fibrillatory Factor in Ventricular Tachycardia

Ventricular Tachycardia

United Kingdom
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

AML | MDS | CMML

United States
Centre Hospitalier William Morey - Chalon sur Saône
Centre Hospitalier Universitaire Dijon

Recruiting

Dynamic Full-Field Optical Coherence Tomography for Structural and Microbiological Characterization of Central Venous Catheter-deposited Biofilm in Critically Ill Patients (OCT-BIO-CVC)

Critically Ill | Central Venous Catheter Associated Bloodstream Infection | Healthcare Associated Infection

France
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

Rectal Cancer

United States
University of Colorado, Denver
National Institute on Aging (NIA)

Active, not recruiting

VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP) (VITAL-NP)

Suspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)

United States
GlaxoSmithKline

Recruiting

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Asthma

United States
GlaxoSmithKline

Recruiting

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Asthma

China
GlaxoSmithKline

Completed

A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine

Rhinitis, Allergic, Perennial and Seasonal

Australia
GlaxoSmithKline

Completed

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

Asthma

Australia
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-342

Rhinitis, Allergic, Perennial

Korea, Republic of
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline
Parexel

Completed

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

Asthma

United States
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
Fujifilm Pharmaceuticals U.S.A., Inc.

Recruiting

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

Advanced Solid Tumors

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

Asthma

United States, Argentina, Japan, Poland, Canada, Russian Federation, Spain, Germany, Hungary, South Africa, Italy, Mexico, Romania, Bulgaria, China, Lithuania
Cochlear
Avania

Completed

CP1150 Sound Processor Speech Perception Compared With the Next Generation of Signal Processing Technology

Hearing Impairment, Sensorineural

Australia
GlaxoSmithKline

Completed

A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function

Asthma

New Zealand
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
Fujifilm Pharmaceuticals U.S.A., Inc.

Recruiting

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors

Advanced Solid Tumors

United States
Mansoura University

Recruiting

Prosthetic Femoral Access for Haemodialysis

Vascular Access Complication

Egypt
Autoimmune Technologies, LLC
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain

Influenza

United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer AJCC v8 | Stage III Renal Pelvis and Ureter Cancer AJCC v8 | Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0a Renal Pelvis and Ureter Cancer AJCC v8 | Stage... and other conditions

United States
Boehringer Ingelheim

Completed

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Healthy
Chiesi Italia
Gesellschaft für Therapieforschung mbH

Not yet recruiting

Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting (TRIMAXIMIZE)

Asthma
Chiesi Italia

Completed

Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)

COPD

Italy
GlaxoSmithKline

Completed

A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis

Rhinitis, Allergic, Perennial and Seasonal

Canada
Autoimmune Technologies, LLC

Completed

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

Influenza

United States
GlaxoSmithKline

Completed

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

Rhinitis, Allergic, Perennial

Australia, Estonia, United States, Germany, Canada, New Zealand, Russian Federation, Lithuania, Latvia
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
Beijing Tongren Hospital
Beijing Institute of Otolaryngology; Shanghai Johnson & Johnson Pharmaceuticals...

Unknown

Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

Determination of the Efficacy of Different Medications for Idiopathic Rhinitis | Impact of Different Medications on Biomarkers of Idiopathic Rhinitis | Safety and Tolerance of Different Medications for Idiopathic Rhinitis

China
GlaxoSmithKline

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

India
GlaxoSmithKline

Completed

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Poland, Romania, Russian Federation, Ukraine
GlaxoSmithKline

Completed

A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects

Pulmonary Disease, Chronic Obstructive

China
Chiesi Italia

Active, not recruiting

Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control (NEWTON)

Asthma

Italy
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium
GlaxoSmithKline

Completed

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Asthma

United States
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Chile, Romania, Canada
GlaxoSmithKline

Completed

A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.

Pulmonary Disease, Chronic Obstructive

Czechia
GlaxoSmithKline

Completed

A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

Asthma

Czechia, Slovakia
GlaxoSmithKline

Completed

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma

Asthma

New Zealand
GlaxoSmithKline

Completed

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Pulmonary Disease, Chronic Obstructive

China
Fujifilm Pharmaceuticals U.S.A., Inc.

Withdrawn

A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)
GlaxoSmithKline

Completed

Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays

Rhinitis, Allergic, Perennial and Seasonal

Argentina, Russian Federation, Korea, Republic of, Australia

3

Subscribe